Tumor Markers

  • Diagnosis
  • Lab Tests
  • References
  • Related Topics

Tumor and Genetic Markers – Use for Specific Malignancy

Tumor and genetic markers may be useful in the diagnosis, treatment, monitoring and prognosis of specific tumors. The recommendations that follow are collected from multiple guideline sources. For specific information regarding use and interpretation of various markers and tests, consultation with a pathologist is highly advised. ARUP Laboratories may not offer all of the tests listed below; consult the Lab Tests section for a list of tests offered.

#-B

1p/19q Deletion by FISH 2008604
Method: Fluorescence in situ Hybridization

5-Hydroxyindoleacetic Acid (HIAA), Urine 0080420
Method: Quantitative High Performance Liquid Chromatography - Tandem Mass Spectrometry

ACTH by Immunohistochemistry 2003427
Method: Immunohistochemistry

Acute Lymphocytic Leukemia (ALL) Panel by FISH, Adult 2002647
Method: Fluorescence in situ Hybridization

Acute Lymphocytic Leukemia (ALL) Panel by FISH, Pediatric 2002719
Method: Fluorescence in situ Hybridization

Acute Myelogenous Leukemia (AML) with Myelodysplastic Syndrome (MDS) or Therapy-Related AML, by FISH 2002653
Method: Fluorescence in situ Hybridization

Acute Myeloid Leukemia Panel by FISH 2011132
Method: Fluorescence in situ Hybridization

Aggressive B-Cell Lymphoma FISH Reflex, Tissue 2012710
Method: Fluorescence in situ Hybridization

ALK (D5F3) by Immunohistochemistry with Reflex to ALK Gene Rearrangements by FISH 2011431
Method: Immunohistochemistry/ Fluorescence in situ Hybridization

ALK (D5F3) with Interpretation by Immunohistochemistry 2007324
Method: Immunohistochemistry

ALK Gene Rearrangements by FISH, Lung 2006102
Method: Fluorescence in situ Hybridization

Alpha Fetoprotein, CSF (Tumor Marker) 0020729
Method: Quantitative Chemiluminescent Immunoassay

Alpha Fetoprotein, Serum (Tumor Marker) 0080428
Method: Quantitative Chemiluminescent Immunoassay

Alpha Fetoprotein, Total and L3 Percent 0081208
Method: Quantitative Liquid Chromatography/Immunoassay

Alpha Subunit, Pituitary Glycoprotein Hormones (PGH) 2013034
Method: Quantitative Chemiluminescent Immunoassay

Alpha-1-Antichymotrypsin (A1ACT) by Immunohistochemistry 2003418
Method: Immunohistochemistry

Alpha-1-Fetoprotein (AFP) by Immunohistochemistry 2003436
Method: Immunohistochemistry

Anaplastic Lymphoma Kinase 1 (ALK-1) by Immunohistochemistry 2003439
Method: Immunohistochemistry

Anti-Human Epithelial Antigen, Ber-EP4 by Immunohistochemistry 2003463
Method: Immunohistochemistry

Arginase 1 by Immunohistochemistry 2011890
Method: Immunohistochemistry

Autoimmune Lymphoproliferative Profile 0095505
Method: Quantitative Flow Cytometry

B Cell Specific Octamer Binding Protein-1 (BOB-1) by Immunohistochemistry 2003442
Method: Immunohistochemistry

B-Cell CD20 Expression 0092099
Method: Flow Cytometry

B-Cell Clonality Screening (IgH and IgK) by PCR 2006193
Method: Polymerase Chain Reaction/Capillary Electrophoresis

BCL-2 by Immunohistochemistry 2004513
Method: Immunohistochemistry

BCL-6 by Immunohistochemistry 2003457
Method: Immunohistochemistry

BCL6 (3q27) Gene Rearrangement by FISH 2010107
Method: Fluorescence in situ Hybridization

BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by Next Generation Sequencing 2008420
Method: Massively Parallel Sequencing

BCR-ABL1, Major (p210), Quantitative 2005017
Method: Quantitative Reverse Transcription Polymerase Chain Reaction

BCR-ABL1, Minor (p190), Quantitative 2005016
Method: Quantitative Reverse Transcription Polymerase Chain Reaction

BCR-ABL1, Qualitative with Reflex to BCR-ABL1 Quantitative 2005010
Method: Reverse Transcription Polymerase Chain Reaction

Beta-2 Microglobulin, Serum or Plasma 0080053
Method: Quantitative Immunoturbidimetry

Beta-Catenin-1 by Immunohistochemistry 2003454
Method: Immunohistochemistry

Beta-hCG, Quantitative (Tumor Marker) 0070029
Method: Quantitative Electrochemiluminescent Immunoassay

Beta-hCG, Quantitative (Tumor Marker), CSF 0020730
Method: Quantitative Electrochemiluminescent Immunoassay

BF-1 by Immunohistochemistry 2003466
Method: Immunohistochemistry

Bladder Tumor Associated Antigen 2000183
Method: Qualitative Immunoassay

BRAF Codon 600 Mutation Detection by Pyrosequencing 2002498
Method: Polymerase Chain Reaction/Pyrosequencing

BRAF Codon 600 Mutation Detection with Reflex to MLH1 Promoter Methylation 0051750
Method: Polymerase Chain Reaction/Pyrosequencing

BRAF V600E Mutation Detection in Circulating Cell-Free DNA by Digital Droplet PCR 2013921
Method: Polymerase Chain Reaction

BRAF V600E Mutation Detection in Hairy Cell Leukemia by Real-Time PCR, Quantitative 2007132
Method: Polymerase Chain Reaction

Breast 2 (GCDFP-15) by Immunohistochemistry 2003472
Method: Immunohistochemistry

Breast and Ovarian Hereditary Cancer Panel, Sequencing and Deletion/Duplication, 20 Genes 2012026
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Breast and Ovarian Hereditary Cancer Syndrome (BRCA1 and BRCA2) Deletion/Duplication 2011915
Method: Multiplex Ligation-dependent Probe Amplification

Breast and Ovarian Hereditary Cancer Syndrome (BRCA1 and BRCA2) Sequencing 2011954
Method: Polymerase Chain Reaction/ Sequencing

Breast and Ovarian Hereditary Cancer Syndrome (BRCA1 and BRCA2) Sequencing and Deletion/Duplication 2011949
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Breast Carcinoma b72.3 by Immunohistochemistry 2003445
Method: Immunohistochemistry

C-D

c-MET by Immunohistochemistry 2008652
Method: Immunohistochemistry

C-MYC by Immunohistochemistry 2008317
Method: Immunohistochemistry

C-Peptide, 120 Minutes 2013562
Method: Quantitative Chemiluminescent Immunoassay

C-Peptide, 180 Minutes 2013564
Method: Quantitative Chemiluminescent Immunoassay

C-Peptide, 30 Minutes 2013558
Method: Quantitative Chemiluminescent Immunoassay

C-Peptide, 60 Minutes 2013560
Method: Quantitative Chemiluminescent Immunoassay

C-Peptide, Serum or Plasma 0070103
Method: Quantitative Chemiluminescent Immunoassay

Calcitonin 0070006
Method: Quantitative Chemiluminescent Immunoassay

Calcitonin by Immunohistochemistry 2003481
Method: Immunohistochemistry

Calcium, Serum or Plasma 0020027
Method: Quantitative Spectrophotometry

Caldesmon by Immunohistochemistry 2003484
Method: Immunohistochemistry

CALR (Calreticulin) Exon 9 Mutation Analysis by PCR 2010673
Method: Polymerase Chain Reaction/Capillary Electrophoresis

Calretinin by Immunohistochemistry 2003490
Method: Immunohistochemistry

Cancer Antigen 125 0080462
Method: Quantitative Electrochemiluminescent Immunoassay

Cancer Antigen 125 by Immunohistochemistry 2003478
Method: Immunohistochemistry

Cancer Antigen 27.29 0080392
Method: Quantitative Chemiluminescent Immunoassay

Cancer Antigen-Breast (CA 15-3) 0080464
Method: Quantitative Electrochemiluminescent Immunoassay

Cancer Antigen-GI (CA 19-9) 0080461
Method: Quantitative Electrochemiluminescent Immunoassay

Cancer Antigen-GI (CA 19-9), Body Fluid 0020746
Method: Quantitative Electrochemiluminescent Immunoassay

Cancer Panel, Hereditary, Deletion/Duplication, 46 Genes 2010757
Method: Exonic Oligonucleotide-based CGH Microarray

Cancer Panel, Hereditary, Sequencing and Deletion/Duplication, 47 Genes 2012032
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Carcinoembryonic Antigen 0080080
Method: Quantitative Electrochemiluminescent Immunoassay

Carcinoembryonic Antigen, Fluid 0020742
Method: Quantitative Electrochemiluminescent Immunoassay

Carcinoembryonic Antigen, Monoclonal (CEA M) by Immunohistochemistry 2003824
Method: Immunohistochemistry

Carcinoembryonic Antigen, Polyclonal (CEA P) by Immunohistochemistry 2003827
Method: Immunohistochemistry

CBFB-MYH11 inv(16) Detection, Quantitative 2011114
Method: Reverse Transcription Quantitative Polymerase Chain Reaction

CD10 (CALLA) by Immunohistochemistry 2003523
Method: Immunohistochemistry

CD117 (c-Kit) by Immunohistochemistry 2003806
Method: Immunohistochemistry

CD138 (Syndecan-1) by Immunohistochemistry 2003812
Method: Immunohistochemistry

CD14 by Immunohistochemistry 2003526
Method: Immunohistochemistry

CD15, Leu M1 by Immunohistochemistry 2003529
Method: Immunohistochemistry

CD19 by Immunohistochemistry 2005114
Method: Immunohistochemistry

CD1a by Immunohistochemistry 2003502
Method: Immunohistochemistry

CD2 by Immunohistochemistry 2003505
Method: Immunohistochemistry

CD20, L26 by Immunohistochemistry 2003532
Method: Immunohistochemistry

CD200 by Immunohistochemistry 2012844
Method: Immunohistochemistry

CD21 (Dendritic Cell) by Immunohistochemistry 2003535
Method: Immunohistochemistry

CD23 by Immunohistochemistry 2003541
Method: Immunohistochemistry

CD25 by Immunohistochemistry 2003544
Method: Immunohistochemistry

CD3 by Immunohistochemistry 2003508
Method: Immunohistochemistry

CD30 (Ki-1) by Immunohistochemistry 2003547
Method: Immunohistochemistry

CD33 by Immunohistochemistry 2003553
Method: Immunohistochemistry

CD34, QBEnd/10 by Immunohistochemistry 2003556
Method: Immunohistochemistry

CD35 by Immunohistochemistry 2003559
Method: Immunohistochemistry

CD4 by Immunohistochemistry 2003511
Method: Immunohistochemistry

CD42b by Immunohistochemistry 2003565
Method: Immunohistochemistry

CD43, L60 (Leu 22) by Immunohistochemistry 2003568
Method: Immunohistochemistry

CD44 by Immunohistochemistry 2003571
Method: Immunohistochemistry

CD45 by Immunohistochemistry 2003574
Method: Immunohistochemistry

CD5 by Immunohistochemistry 2003514
Method: Immunohistochemistry

CD52 (CAMPATH-1) by Immunohistochemistry 2003586
Method: Immunohistochemistry

CD56 (NCAM) by Immunohistochemistry 2003589
Method: Immunohistochemistry

CD57 by Immunohistochemistry 2003592
Method: Immunohistochemistry

CD61 (Platelet Glycoprotein IIIA) by Immunohistochemistry 2003595
Method: Immunohistochemistry

CD68, KP1 by Immunohistochemistry 2003598
Method: Immunohistochemistry

CD7 by Immunohistochemistry 2003517
Method: Immunohistochemistry

CD79A by Immunohistochemistry 2003800
Method: Immunohistochemistry

CD8 by Immunohistochemistry 2003520
Method: Immunohistochemistry

CDK4 by Immunohistochemistry 2005534
Method: Immunohistochemistry

CDX2 by Immunohistochemistry 2003821
Method: Immunohistochemistry

CEBPA Mutation Detection 2004247
Method: Polymerase Chain Reaction/Sequencing

Central Nervous System Hereditary Cancer Panel, Sequencing and Deletion/Duplication, 15 Genes 2010188
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Chromogranin A 0080469
Method: Quantitative Enzyme Immunoassay

Chromogranin A by Immunohistochemistry 2003830
Method: Immunohistochemistry

Chromosome Analysis, Bone Marrow 2002292
Method: Giemsa Band

Chromosome Analysis, Bone Marrow with Reflex to Genomic Microarray 2007130
Method: Giemsa Band/Genomic Microarray (Oligo-SNP array)

Chromosome Analysis, Leukemic Blood 2002290
Method: Giemsa Band

Chromosome Analysis, Leukemic Blood with Reflex to Genomic Microarray 2007131
Method: Giemsa Band/Genomic Microarray (Oligo-SNP array)

Chromosome Analysis, Solid Tumor 2002296
Method: Giemsa Band

Chromosome FISH, CLL Panel 2002295
Method: Fluorescence in situ Hybridization

Chromosome FISH, Interphase 2002298
Method: Fluorescence in situ Hybridization

Circulating Tumor Cell Count 0093399
Method: Immunomagnetic Separation/Immunofluorescent Stain/Computer Assisted Analysis

Colon Cancer Gene Panel, Somatic 2011616
Method: Mass Spectrometry

Cyclin D1, SP4 by Immunohistochemistry 2003842
Method: Immunohistochemistry

CYFRA 21-1 (Cytokeratin 19 Fragment), Serum 0081344
Method: Quantitative Enzyme-Linked Immunosorbent Assay

Cytogenomic Molecular Inversion Probe Array, FFPE Tissue - Oncology 2010229
Method: Molecular Inversion Probe Array

Cytogenomic SNP Microarray - Oncology 2006325
Method: Genomic Microarray (Oligo-SNP Array)

Cytokeratin 19 (CK 19) by Immunohistochemistry 2003845
Method: Immunohistochemistry

Cytokeratin 20 (CK 20) by Immunohistochemistry 2003848
Method: Immunohistochemistry

Cytokeratin 5,6 (CK 5,6) by Immunohistochemistry 2003851
Method: Immunohistochemistry

Cytokeratin 7 (CK 7) by Immunohistochemistry 2003854
Method: Immunohistochemistry

Cytokeratin 8,18 Low Molecular Weight (CAM 5.2) by Immunohistochemistry 2003493
Method: Immunohistochemistry

Cytology, Fine Needle Aspirate 2000443
Method: Microscopy

Cytology, Non-Gynecologic 2000623
Method: Microscopy

Cytology, SurePath Liquid-Based Pap Test 2000134
Method: Microscopy

Cytology, SurePath Liquid-Based Pap Test and Human Papillomavirus (HPV), High Risk by PCR, SurePath (for routine co-testing in women over 30) 2000133
Method: Microscopy/Qualitative Polymerase Chain Reaction

Cytology, SurePath Liquid-Based Pap Test with Reflex to Human Papillomavirus (HPV), High Risk by PCR, SurePath 2000135
Method: Microscopy/ Qualitative Polymerase Chain Reaction

Cytology, ThinPrep Pap Test 2000137
Method: ThinPrep 2000 System/Routine Cytopathologic Evaluation

Cytology, ThinPrep Pap Test and Human Papillomavirus (HPV), High Risk, E6/E7 mRNA by Transcription-Mediated Amplification (TMA) (for routine co-testing in women over 30) 2000136
Method: Microscopy/Qualitative Transcription-mediated Amplification

Cytology, ThinPrep Pap Test with Reflex to Human Papillomavirus (HPV), High Risk, E6/E7 mRNA by Transcription-Mediated Amplification (TMA) 2000138
Method: Microscopy/Qualitative Transcription-mediated Amplification

D2-40 by Immunohistochemistry 2003857
Method: Immunohistochemistry

DDIT3 (CHOP) (12q13) Gene Rearrangement by FISH 2007223
Method: Fluorescence in situ Hybridization

Des-gamma-carboxy Prothrombin 0081312
Method: Quantitative Liquid Chromatography/Immunoassay

Desmin by Immunohistochemistry 2003863
Method: Immunohistochemistry

DNA Cell Cycle Analysis - Ploidy and S-Phase 0095155
Method: Quantitative Flow Cytometry

DOG1 by Immunohistochemistry 2010168
Method: Immunohistochemistry

E-H

E-Cadherin by Immunohistochemistry 2003869
Method: Immunohistochemistry

EGFR Mutation Detection by Pyrosequencing 2002440
Method: Polymerase Chain Reaction/Pyrosequencing

EGFR T790M Mutation Detection in Circulating Tumor DNA by Digital Droplet PCR 2012868
Method: Polymerase Chain Reaction

Endocrine Hereditary Cancer Panel, Sequencing and Deletion/Duplication, 13 Genes 2010193
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Eosinophilia Panel by FISH 2002378
Method: Fluorescence in situ Hybridization

Epi proColon 2013906
Method: Polymerase Chain Reaction

Epithelial Membrane Antigen (EMA) by Immunohistochemistry 2003872
Method: Immunohistochemistry

Epithelial-Related Antigen, MOC-31 by Immunohistochemistry 2003875
Method: Immunohistochemistry

Epstein-Barr Virus (EBV) by in situ Hybridization, Paraffin 2002902
Method: In situ Hybridization

Epstein-Barr Virus (EBV) by In Situ Hybridization, Stain Only 2013592
Method: In Situ Hybridization

ERBB2 (HER2) (HercepTest) by Immunohistochemistry 2007332
Method: Immunohistochemistry

ERBB2 (HER2/neu) (HercepTest) by Immunohistochemistry, Tissue with Reflex to FISH if 2+ 0049178
Method: Immunohistochemistry

ERBB2 (HER2/neu) (HercepTest) with Interpretation by Immunohistochemistry, Tissue 0049174
Method: Immunohistochemistry

ERBB2 (HER2/neu) Gene Amplification by FISH, Tissue 2008603
Method: Fluorescence in situ Hybridization

ERG by Immunohistochemistry 2012555
Method: Immunohistochemistry

Esterase Stain, Nonspecific 0049050
Method: Cytochemical Stain

Esterase, Non-Specific Cytochemical Stain Only 2013277
Method: Cytochemical Stain

Estrogen Receptor (ER) by Immunohistochemistry 2004516
Method: Immunohistochemistry

Estrogen/Progesterone Receptor with Interpretation by Immunohistochemistry 0049210
Method: Immunohistochemistry

Ewing Sarcoma (O13) by Immunohistochemistry 2004055
Method: Immunohistochemistry

EWSR1 (22q12) Gene Rearrangement by FISH 2007225
Method: Fluorescence in situ Hybridization

Factor XIIIa by Immunohistochemistry 2003878
Method: Immunohistochemistry

Familial Adenomatous Polyposis (APC) Sequencing 2004863
Method: Polymerase Chain Reaction/Sequencing

Familial Adenomatous Polyposis Panel: (APC) Sequencing and Deletion/Duplication, (MUTYH) 2 Mutations 2004915
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

FLT3 Mutation Detection by PCR 2005400
Method: Qualitative Polymerase Chain Reaction/Capillary Electrophoresis

FLT3 Signal Ratio Mutation Detection by PCR 2011806
Method: Qualitative Polymerase Chain Reaction/Capillary Electrophoresis

FOXO1 (FKHR) (13q14) Gene Rearrangement by FISH 2001497
Method: Fluorescence in situ Hybridization

Friend Leukemia Integration-1 (Fli-1) by Immunohistochemistry 2003887
Method: Immunohistochemistry

Gastrin 0070075
Method: Quantitative Chemiluminescent Immunoassay

Gastrin by Immunohistochemistry 2003896
Method: Immunohistochemistry

Gastrointestinal Hereditary Cancer Panel, Sequencing and Deletion/Duplication, 16 Genes 2013449
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray/Sequencing/Multiplex Ligation-dDependent Probe Amplification

Gastrointestinal Stromal Tumor Mutation 2002674
Method: Polymerase Chain Reaction/Sequencing

GATA3 by Immunohistochemistry 2012558
Method: Immunohistochemistry

Glial Fibrillary Acidic Protein (GFAP) by Immunohistochemistry 2003899
Method: Immunohistochemistry

Glucagon 0099165
Method: Quantitative Radioimmunoassay

Glycophorin A by Immunohistochemistry 2003908
Method: Immunohistochemistry

Glypican 3 by Immunohistochemistry 2011925
Method: Immunohistochemistry

Granzyme B by Immunohistochemistry 2007173
Method: Immunohistochemistry

Growth Hormone 0070080
Method: Quantitative Chemiluminescent Immunoassay

Growth Hormone by Immunohistochemistry 2003929
Method: Immunohistochemistry

Hairy Cell Leukemia, DBA.44 by Immunohistochemistry 2003860
Method: Immunohistochemistry

HBME-1 (Mesothelial Cell) by Immunohistochemistry 2003914
Method: Immunohistochemistry

Helicobacter pylori by Immunohistochemistry 2003941
Method: Immunohistochemistry

Hepatocellular Carcinoma Tumor Marker Panel 0081326
Method: Quantitative Liquid Chromatography/Immunoassay

Hepatocyte Specific Antigen (HSA) by Immunohistochemistry 2003923
Method: Immunohistochemistry

HER2/neu Quantitative by ELISA 2004672
Method: Quantitative Enzyme-Linked Immunosorbent Assay

Hereditary Paraganglioma-Pheochromocytoma (SDHA) Sequencing 2011461
Method: Polymerase Chain Reaction/Sequencing

Hereditary Paraganglioma-Pheochromocytoma (SDHB) Sequencing and Deletion/Duplication 2007108
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Hereditary Paraganglioma-Pheochromocytoma (SDHB, SDHC, and SDHD) Deletion/Duplication 2007113
Method: Polymerase Chain Reaction/Multiplex Ligation-dependent Probe Amplification

Hereditary Paraganglioma-Pheochromocytoma (SDHB, SDHC, and SDHD) Sequencing and Deletion/Duplication Panel 2007167
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Hereditary Paraganglioma-Pheochromocytoma (SDHC) Sequencing and Deletion/Duplication 2007117
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Hereditary Paraganglioma-Pheochromocytoma (SDHD) Sequencing and Deletion/Duplication 2007122
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Herpes Virus 8 by Immunohistochemistry 2003932
Method: Immunohistochemistry

HNPCC/Lynch Syndrome (MLH1) Sequencing and Deletion/Duplication 0051650
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

HNPCC/Lynch Syndrome (MSH2) Sequencing and Deletion/Duplication 0051654
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

HNPCC/Lynch Syndrome (MSH6) Sequencing and Deletion/Duplication 0051656
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

HNPCC/Lynch Syndrome (PMS2) Sequencing and Deletion/Duplication 0051737
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

HNPCC/Lynch Syndrome Deletion/Duplication 2001728
Method: Polymerase Chain Reaction/Multiplex Ligation-dependent Probe Amplification

Homovanillic Acid (HVA), Urine 0080422
Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Human Chorionic Gonadotropin (Beta-hCG) by Immunohistochemistry 2003920
Method: Immunohistochemistry

Human Epididymis Protein 4 (HE4) 2003020
Method: Quantitative Enzyme Immunoassay

Human Papillomavirus (HPV) Genotypes 16 and 18/45 by Transcription-Mediated Amplification (TMA), ThinPrep 2007894
Method: Qualitative Transcription-Mediated Amplification

Human Papillomavirus (HPV), High Risk by Hybrid Capture, Cervical Brush 0065999
Method: Qualitative Nucleic Acid Probe

Human Papillomavirus (HPV), High Risk by Hybrid Capture, ThinPrep 2008404
Method: Qualitative Nucleic Acid Probe

Human Papillomavirus (HPV), High Risk by in situ Hybridization, Paraffin 2002899
Method: In situ Hybridization

Human Papillomavirus (HPV), High Risk by PCR, SurePath 2011942
Method: Qualitative Polymerase Chain Reaction

Human Papillomavirus (HPV), High Risk by PCR, ThinPrep 2011947
Method: Qualitative Polymerase Chain Reaction

Human Papillomavirus (HPV), High Risk by Transcription-Mediated Amplification (TMA) with Reflex to HPV Genotypes 16 and 18/45 by TMA, ThinPrep 2007890
Method: Qualitative Transcription-Mediated Amplification

Human Papillomavirus (HPV), High Risk by Transcription-Mediated Amplification (TMA), ThinPrep 2007893
Method: Qualitative Transcription-Mediated Amplification

Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, SurePath 2011933
Method: Qualitative Polymerase Chain Reaction

Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, ThinPrep 2011940
Method: Qualitative Polymerase Chain Reaction

Human Placental Lactogen (HPL) by Immunohistochemistry 2003938
Method: Immunohistochemistry

Human T-Lymphotropic Virus (HTLV) Types I/II Antibodies by ELISA with Reflex to HTLV-I/II Confirmation by Western Blot 0051164
Method: Qualitative Enzyme-Linked Immunosorbent Assay/Qualitative Western Blot

Human T-Lymphotropic Virus Types I/II Antibodies, Western Blot 0020642
Method: Qualitative Western Blot

I-M

IDH1 and IDH2 Mutation Analysis, exon 4 2006444
Method: Polymerase Chain Reaction/Sequencing

IDH1 R132H by Immunohistochemistry 2005857
Method: Immunohistochemistry

IDH1 R132H Point Mutation with Interpretation by Immunohistochemistry 2007357
Method: Immunohistochemistry

IGF-1 (Insulin-Like Growth Factor 1) 0070125
Method: Quantitative Chemiluminescent Immunoassay

IGH-BCL2 Fusion, t(14;18) by FISH 2001536
Method: Fluorescence in situ Hybridization

IGH-CCND1 (BCL-1/JH) Translocation, t(11;14) by PCR 0055557
Method: Polymerase Chain Reaction

IGH-CCND1 Fusion, t(11;14) by FISH 2007226
Method: Fluorescence in situ Hybridization

IGH-MYC Fusion t(8;14) by FISH 2001538
Method: Fluorescence in situ Hybridization

IGHV Mutation Analysis by Sequencing 0040227
Method: Polymerase Chain Reaction/Sequencing

Immunofixation Electrophoresis, Qualitative, Gel 2012572
Method: Qualitative Immunofixation Electrophoresis

Inhibin A (Dimer) 0070137
Method: Quantitative Chemiluminescent Immunoassay

Inhibin B 0070413
Method: Quantitative Enzyme-Linked Immunosorbent Assay

Inhibin by Immunohistochemistry 2003969
Method: Immunohistochemistry

INI1 (BAF47) by Immunohistochemistry 2003448
Method: Immunohistochemistry

Insulin, Fasting 0070063
Method: Quantitative Chemiluminescent Immunoassay

Insulin-Like Growth Factor 2 2013599
Method: Quantitative Enzyme-Linked Immunosorbent Assay

JAK2 Exon 12 Mutation Analysis by PCR 2002357
Method: Polymerase Chain Reaction

JAK2 Gene, V617F Mutation, Qualitative 0051245
Method: Polymerase Chain Reaction

JAK2 Gene, V617F Mutation, Qualitative with Reflex to CALR (Calreticulin) Exon 9 Mutation Analysis by PCR with Reflex to MPL codon 515 Mutation Detection by Pyrosequencing, Quantitative 2012084
Method: Polymerase Chain Reaction/Capillary Electrophoresis/Pyrosequencing

JAK2 Gene, V617F Mutation, Qualitative with Reflex to JAK2 Exon 12 Mutation Analysis by PCR 2012085
Method: Polymerase Chain Reaction

JAK2 Gene, V617F Mutation, Quantitative 0040168
Method: Polymerase Chain Reaction

Juvenile Polyposis (SMAD4) Deletion/Duplication 2001976
Method: Polymerase Chain Reaction/Multiplex Ligation-dependent Probe Amplification

Juvenile Polyposis (SMAD4) Sequencing 0051510
Method: Polymerase Chain Reaction/ Sequencing

Juvenile Polyposis (SMAD4) Sequencing and Deletion/Duplication 2001971
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Juvenile Polyposis Syndrome (BMPR1A) Deletion/Duplication 2004984
Method: Polymerase Chain Reaction/Multiplex Ligation-dependent Probe Amplification

Juvenile Polyposis Syndrome (BMPR1A) Sequencing 2004988
Method: Polymerase Chain Reaction/Sequencing

Juvenile Polyposis Syndrome (BMPR1A) Sequencing and Deletion/Duplication 2004992
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Kappa and Lambda Free Light Chains (Bence Jones Protein), Qualitative, Urine 0050161
Method: Qualitative Immunofixation Electrophoresis/Quantitative Nephelometry

Kappa and Lambda Free Light Chains (Bence Jones Protein), Quantitative, Urine 0050618
Method: Qualitative Immunofixation Electrophoresis/Quantitative Nephelometry

Kappa Light Chains by Immunohistochemistry 2003981
Method: Immunohistochemistry

Kappa/Lambda Light Chain Panel by In Situ Hybridization, Stain Only 2013595
Method: In Situ Hybridization

Kappa/Lambda Quantitative Free Light Chains with Ratio, Serum 0055167
Method: Quantitative Nephelometry

Keratin 903 (K903) High Molecular Weight by Immunohistochemistry 2003978
Method: Immunohistochemistry

Ki-67 with Interpretation by Immunohistochemistry 2007182
Method: Immunohistochemistry

Ki-67, MIB-1, by Immunohistochemistry 2004519
Method: Immunohistochemistry

KIT (D816V) Mutation by PCR 0040137
Method: Polymerase Chain Reaction

KIT D816V Mutation Detection by PCR for Gleevec Eligibility in Aggressive Systemic Mastocytosis (ASM) 2012207
Method: Polymerase Chain Reaction

KIT Mutations in AML by Fragment Analysis and Sequencing 2002437
Method: Polymerase Chain Reaction/Fragment Analysis/Sequencing

KIT Mutations, Melanoma 2002695
Method: Polymerase Chain Reaction/Sequencing

KRAS Mutation Detection 0040248
Method: Polymerase Chain Reaction/Pyrosequencing

KRAS Mutation Detection with Reflex to BRAF Codon 600 Mutation Detection 2001932
Method: Polymerase Chain Reaction/Pyrosequencing

Lactate Dehydrogenase, Serum or Plasma 0020006
Method: Quantitative Enzymatic

Lambda Light Chains by Immunohistochemistry 2003984
Method: Immunohistochemistry

Leukemia/Lymphoma Phenotyping by Flow Cytometry 2008003
Method: Flow Cytometry

Leukocyte Alkaline Phosphatase 0049000
Method: Cytochemical Stain

Lipid Associated Sialic Acid 0080467
Method: Quantitative Spectrophotometry

Lung Cancer Panel 2008894
Method: Polymerase Chain Reaction/Pyrosequencing/Immunohistochemistry

Lung Cancer Panel with KRAS 2008895
Method: Polymerase Chain Reaction/Pyrosequencing/Immunohistochemistry

Luteinizing Hormone and Follicle Stimulating Hormone 0070193
Method: Quantitative Electrochemiluminescent Immunoassay

Lymphoma (Aggressive) Panel by FISH 2002650
Method: Fluorescence in situ Hybridization

Lysozyme (Muramidase) by Immunohistochemistry 2003990
Method: Immunohistochemistry

Macroprolactin 0020765
Method: Quantitative Chemiluminescent Immunoassay

Mast Cell Tryptase by Immunohistochemistry 2003993
Method: Immunohistochemistry

MDM2 by Immunohistochemistry 2005848
Method: Immunohistochemistry

MDM2 Gene Amplification by FISH 2003016
Method: Fluorescence in situ Hybridization

Melan A by Immunohistochemistry 2003996
Method: Immunohistochemistry

Melanoma Antibody, HMB45 by Immunohistochemistry 2003935
Method: Immunohistochemistry

Melanoma Hereditary Cancer Panel, Sequencing and Deletion/Duplication, 6 Genes 2010209
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

MET Gene Amplification by FISH 2013082
Method: Fluorescence in situ Hybridization

Metanephrines Fractionated by HPLC-MS/MS, Urine 2007996
Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Metanephrines, Plasma (Free) 0050184
Method: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

MGMT Methylation Detection by PCR 2009310
Method: Real-Time Polymerase Chain Reaction/Fluorescence Resonance Energy Transfer

Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR 0051740
Method: Polymerase Chain Reaction/Fragment Analysis

Mismatch Repair by Immunohistochemistry 0049302
Method: Qualitative Immunohistochemistry

Mismatch Repair by Immunohistochemistry with Reflex to BRAF Codon 600 Mutation and MLH1 Promoter Methylation 2002327
Method: Qualitative Immunohistochemistry/Qualitative Real-time Polymerase Chain Reaction

Mismatch Repair by Immunohistochemistry with Reflex to MLH1 Promoter Methylation 2005270
Method: Qualitative Immunohistochemistry/Qualitative Real-time Polymerase Chain Reaction

MITF by Immunohistochemistry 2011998
Method: Immunohistochemistry

MLH1 Promoter Methylation, Paraffin 2002499
Method: Real-Time Polymerase Chain Reaction/Fluorescence Resonance Energy Transfer

Molar Pregnancy, 16 DNA Markers 0051755
Method: Polymerase Chain Reaction/Fragment Analysis

MPL codon 515 Mutation Detection by Pyrosequencing, Quantitative 2005545
Method: Polymerase Chain Reaction/Quantitative Pyrosequencing

Muc-1 by Immunohistochemistry 2004002
Method: Immunohistochemistry

Muc-4 by Immunohistochemistry 2004008
Method: Immunohistochemistry

Muc-5AC by Immunohistochemistry 2003999
Method: Immunohistochemistry

Multiple Endocrine Neoplasia Type 1 (MEN1) Sequencing and Deletion/Duplication 2005360
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Multiple Endocrine Neoplasia Type 2 (MEN2), RET Gene Mutations by Sequencing 0051390
Method: Polymerase Chain Reaction/Sequencing

Multiple Myeloma Panel by FISH 2002294
Method: Fluorescence in situ Hybridization

MUM1/IRF4 by Immunohistochemistry 2003975
Method: Immunohistochemistry

Muscle-Specific Actin (MSA) by Immunohistochemistry 2004011
Method: Immunohistochemistry

MUTYH-Associated Polyposis (MUTYH) 2 Mutations 2004911
Method: Polymerase Chain Reaction/Sequencing

MUTYH-Associated Polyposis (MUTYH) Sequencing 2006191
Method: Polymerase Chain Reaction/Sequencing

MYC (8q24) Gene Rearrangement by FISH 2002345
Method: Fluorescence in situ Hybridization

MYCN (N-MYC) Gene Amplification by FISH 2007227
Method: Fluorescence in situ Hybridization

MYD88 L265P Mutation Detection by PCR, Quantitative 2009318
Method: Real-time Polymerase Chain Reaction

Myelodysplastic Syndrome (MDS) Panel by FISH 2002709
Method: Fluorescence in situ Hybridization

Myeloid Malignancies Mutation Panel by Next Generation Sequencing 2011117
Method: Massively Parallel Sequencing

Myeloid Malignancies Somatic Mutation and Copy Number Analysis Panel 2012182
Method: Massively Parallel Sequencing/Genomic Microarray (Oligo-SNP Array)

Myeloperoxidase (MPO) by Immunohistochemistry 2004014
Method: Immunohistochemistry

Myeloperoxidase, Cytochemical Stain Only 2013273
Method: Cytochemical Stain

Myeloproliferative Disorders Panel by FISH 2002360
Method: Fluorescence in situ Hybridization

Myogenin (Myf4) by Immunohistochemistry 2004017
Method: Immunohistochemistry

Myoglobin by Immunohistochemistry 2004031
Method: Immunohistochemistry

Myosin by Immunohistochemistry 2004034
Method: Immunohistochemistry

N-P

Napsin A by Immunohistochemistry 2008716
Method: Immunohistochemistry

Neurofilament by Immunohistochemistry 2004049
Method: Immunohistochemistry

Neuron Specific Enolase 0098198
Method: Quantitative Enzyme-Linked Immunosorbent Assay

Neuron Specific Enolase, CSF 0081226
Method: Quantitative Enzyme-Linked Immunosorbent Assay

Neuron Specific Enolase, Polyclonal (NSE P) by Immunohistochemistry 2004052
Method: Immunohistochemistry

Neuronal Nuclei (NeuN) by Immunohistochemistry 2004046
Method: Immunohistochemistry

NMP22, Urine 0080281
Method: Quantitative Enzyme Immunoassay

NPM1 Mutation by PCR and Fragment Analysis 0040174
Method: Polymerase Chain Reaction/Fragment Analysis

NRAS Mutation Detection by Pyrosequencing 2003123
Method: Polymerase Chain Reaction/Pyrosequencing

Octamer Transcription Factor-2 (Oct 2) by Immunohistochemistry 2004061
Method: Immunohistochemistry

Octamer Transcription Factor-3 and -4 (Oct 3/4) by Immunohistochemistry 2004058
Method: Immunohistochemistry

p16 by Immunohistochemistry 2004064
Method: Immunohistochemistry

p21 (Waf1/Cip 1) by Immunohistochemistry 2004067
Method: Immunohistochemistry

P40 by Immunohistochemistry 2010142
Method: Immunohistochemistry

P504S (AMACR) by Immunohistochemistry 2004076
Method: Immunohistochemistry

p53 by Immunohistochemistry 2004522
Method: Immunohistochemistry

p53 with Interpretation by Immunohistochemistry 0049250
Method: Immunohistochemistry

p63 by Immunohistochemistry 2004073
Method: Immunohistochemistry

Pan Cytokeratin (AE1,3) by Immunohistochemistry 2003433
Method: Immunohistochemistry

Pancreatic Polypeptide 0099436
Method: Quantitative Radioimmunoassay

Pancreatitis (PRSS1) Sequencing 2002016
Method: Polymerase Chain Reaction/Sequencing

Pancreatobiliary FISH 2002528
Method: Fluorescence in situ Hybridization/Computer Assisted Analysis/Microscopy

Parathyroid Hormone (PTH) by Immunohistochemistry 2004118
Method: Immunohistochemistry

Parathyroid Hormone, Intact with Calcium 0070172
Method: Quantitative Electrochemiluminescent Immunoassay

Parathyroid Hormone-Related Peptide (PTHrP) by LC-MS/MS, Plasma 2010677
Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Pax-5 by Immunohistochemistry 2004082
Method: Immunohistochemistry

PAX2 by Immunohistochemistry 2006291
Method: Immunohistochemistry

PAX8 by Immunohistochemistry 2010787
Method: Immunohistochemistry

PCA3 - Prostate Cancer Biomarker by Transcription-Mediated Amplification 2010102
Method: Qualitative Transcription-Mediated Amplification

PD-1 by Immunohistochemistry 2004085
Method: Immunohistochemistry

PD-1 by Immunohistochemistry with Interpretation (INACTIVE as of 12/05/2016: Refer to 2004085) 2012912
Method: Immunohistochemistry

PD-L1 22C3 pharmDx by Immunohistochemistry with Interpretation, pembrolizumab (KEYTRUDA) 2013284
Method: Immunohistochemistry

PD-L1 28-8 pharmDx by Immunohistochemistry with Interpretation, nivolumab (OPDIVO) 2013684
Method: Immunohistochemistry

PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) 2012147
Method: Fluorescence in situ Hybridization

Peutz-Jeghers Syndrome (STK11) Deletion/Duplication 2008377
Method: Multiplex Ligation-dependent Probe Amplification

Peutz-Jeghers Syndrome (STK11) Sequencing 2008394
Method: Polymerase Chain Reaction/Sequencing

Peutz-Jeghers Syndrome (STK11) Sequencing and Deletion/Duplication 2008398
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

PIK3CA Mutation Detection 2004510
Method: Polymerase Chain Reaction/Pyrosequencing

PIN4 Prostate Triple Stain by Immunohistochemistry 2010045
Method: Immunohistochemistry

Placental Alkaline Phosphatase (PLAP) by Immunohistochemistry 2004097
Method: Immunohistochemistry

PML-RARA Translocation by FISH 2002363
Method: Fluorescence in situ Hybridization

PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative 2002871
Method: Reverse Transcription Polymerase Chain Reaction

Progesterone Receptor (PR) by Immunohistochemistry 2004525
Method: Immunohistochemistry

Proinsulin, Intact 0070112
Method: Quantitative Chemiluminescent Immunoassay

Proinsulin, Intact/Insulin Ratio 0070256
Method: Quantitative Chemiluminescent Immunoassay/Quantitative Chemiluminescent Immunoassay

Prolactin by Immunohistochemistry 2004109
Method: Immunohistochemistry

Prolactin, Dilution Study 0020724
Method: Quantitative Chemiluminescent Immunoassay

Prosigna Breast Cancer Prognostic Gene Signature 2010248
Method: Hybridization/gene expression

Prostate Specific Antigen by Immunohistochemistry 2004112
Method: Immunohistochemistry

Prostate Specific Antigen, Complexed 2002930
Method: Chemiluminescent Immunoassay

Prostate Specific Antigen, Free Percentage (Includes Free PSA and Total PSA) 0080206
Method: Quantitative Electrochemiluminescent Immunoassay

Prostate Specific Antigen, Total 0070121
Method: Quantitative Electrochemiluminescent Immunoassay

Prostate Specific Antigen, Total with Reflex to Free PSA (Includes Free Percentage) 0080264
Method: Quantitative Electrochemiluminescent Immunoassay

Prostate Specific Antigen, Ultrasensitive 0098581
Method: Quantitative Electrochemiluminescent Immunoassay

Prostatic Acid Phosphatase (PAP) by Immunohistochemistry 2004079
Method: Immunohistochemistry

Protein Electrophoresis with Reflex to Immunofixation Electrophoresis Monoclonal Protein Detection, Quantitation & Characterization, IgA, IgG, & IgM, Serum 2002109
Method: Quantitative Capillary Electrophoresis/Qualitative Immunofixation Electrophoresis/Quantitative Nephelometry

Protein Electrophoresis, CSF 0050590
Method: Quantitative Electrophoresis

Protein Gene Product (PGP) 9.5 by Immunohistochemistry 2004091
Method: Immunohistochemistry

PTEN by Immunohistochemistry 2004115
Method: Immunohistochemistry

PTEN with Interpretation by Immunohistochemistry 2007031
Method: Immunohistochemistry

PTEN-Related Disorders (PTEN) Sequencing and Deletion/Duplication 2002470
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Q-Z

Renal Cell Carcinoma (RCC) Antigen by Immunohistochemistry 2004124
Method: Immunohistochemistry

Renal Hereditary Cancer Panel, Sequencing and Deletion/Duplication, 15 Genes 2010214
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

ROS1 by FISH 2008418
Method: Fluorescence in situ Hybridization

ROS1 with Interpretation by Immunohistochemistry with Reflex to FISH if Equivocal 2008414
Method: Immunohistochemistry

RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Detection, Quantitative 2010138
Method: Quantitative Reverse Transcription Polymerase Chain Reaction

S-100 Protein by Immunohistochemistry 2004127
Method: Immunohistochemistry

S-100B Protein, Serum 2001766
Method: Quantitative Enzyme-Linked Immunosorbent Assay

Sal-like 4 (SALL4) by Immunohistochemistry 2005432
Method: Immunohistochemistry

SDHB with Interpretation by Immunohistochemistry 2006948
Method: Immunohistochemistry

Serotonin, Serum 0080397
Method: Quantitative High Performance Liquid Chromatography

Serotonin, Whole Blood 0080395
Method: Quantitative High Performance Liquid Chromatography

Sezary Cell Exam 0049180
Method: Stain

Smad4 by Immunohistochemistry 2006403
Method: Immunohistochemistry

Smooth Muscle Actin (SMA) by Immunohistochemistry 2004130
Method: Immunohistochemistry

Solid Tumor Mutation Panel by Next Generation Sequencing 2007991
Method: Massively Parallel Sequencing

Soluble Mesothelin Related Peptides (MESOMARK) 0081284
Method: Quantitative Enzyme-Linked Immunosorbent Assay

SOX11 by Immunohistochemistry 2012561
Method: Immunohistochemistry

Squamous Cell Carcinoma Antigen, Serum 0081054
Method: Quantitative Enzyme-Linked Immunosorbent Assay

SS18 (SYT) (18q11) Gene Rearrangement by FISH 2007222
Method: Fluorescence in situ Hybridization

STAT6 by Immunohistochemistry 2013251
Method: Immunohistochemistry

Synaptophysin by Immunohistochemistry 2004139
Method: Immunohistochemistry

T-Cell Clonality by Flow Cytometry Analysis of TCR V-Beta 0093199
Method: Flow Cytometry

T-Cell Clonality by Next Generation Sequencing 2008409
Method: Massively Parallel Sequencing

T-Cell Clonality Screening by PCR 0055567
Method: Polymerase Chain Reaction/Capillary Electrophoresis

T-cell Intracytoplasmic Antigen (TIA-1) by Immunohistochemistry 2004148
Method: Immunohistochemistry

Tartrate-Resistant Acid Phosphatase (TRAP) by Immunohistochemistry 2004160
Method: Immunohistochemistry

Tartrate-Resistant Acid Phosphatase, Cytochemical Stain Only 2013275
Method: Cytochemical Stain

TdT by Immunohistochemistry 2004142
Method: Immunohistochemistry

TFE3 by Immunohistochemistry 2010688
Method: Immunohistochemistry

Thyroglobulin Antibody 0050105
Method: Quantitative Chemiluminescent Immunoassay

Thyroglobulin by Immunohistochemistry 2004145
Method: Immunohistochemistry

Thyroglobulin by LC-MS/MS, Serum or Plasma 2006550
Method: High Performance Liquid Chromatography-Tandem Mass Spectrometry

Thyroglobulin, Fine Needle Aspiration (FNA) 0020753
Method: Quantitative Chemiluminescent Immunoassay

Thyroglobulin, Serum or Plasma with Reflex to LC-MS/MS or CIA 2006685
Method: Quantitative Chemiluminescent Immunoassay/High Performance Chromatography-Tandem Mass

Thyroid Stimulating Hormone 0070145
Method: Quantitative Chemiluminescent Immunoassay

Thyroid Transcription Factor (TTF-1) by Immunohistochemistry 2004166
Method: Immunohistochemistry

UDP Glucuronosyltransferase 1A1 (UGT1A1) Genotyping 0051332
Method: Polymerase Chain Reaction/Fragment Analysis

Ulex Europaeus Agglutinin 1 (UEA-1) by Immunohistochemistry 2004172
Method: Immunohistochemistry

UroVysion FISH 2001181
Method: Fluorescence in situ Hybridization/Computer Assisted Analysis/Microscopy

Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA), Urine 0080470
Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Vanillylmandelic Acid (VMA), Urine 0080421
Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Vasoactive Intestinal Peptide 0099435
Method: Quantitative Radioimmunoassay

Vimentin by Immunohistochemistry 2004181
Method: Immunohistochemistry

von Hippel-Lindau (VHL) Sequencing and Deletion/Duplication 2002965
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Wilms Tumor (WT-1), N-terminus by Immunohistochemistry 2004184
Method: Immunohistochemistry

WT1 Mutation Detection by Sequencing 2005766
Method: Polymerase Chain Reaction/Sequencing

ZAP-70 Analysis by Flow Cytometry (Temporary Referral as of 08/05/16) 0092392
Method: Flow Cytometry

Guidelines

Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010; 8 Suppl 2: S1-41; quiz S42-4. PubMed

Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014; 134(11): 2513-22. PubMed

Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010; 21(3): 441-7. PubMed

Hammond EH, Hayes DF, Dowsett M, Allred C, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne K, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams B, Wittliff JL, Wolff AC, American Society of Clinical Oncology, College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134(7): e48-72. PubMed

National Academy of Clinical Biochemistry Practice Guidelines. American Association for Clinical Chemistry. Washington, DC [Accessed: Nov 2015]

NCCN Clinical Practice Guidelines. National Comprehensive Cancer Network. Fort Washington, PA [Accessed: Nov 2015]

O'Toole D, Grossman A, Gross D, Fave GD, Barkmanova J, O'Connor J, Pape U, Plöckinger U, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009; 90(2): 194-202. PubMed

Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010; 60(2): 99-119. PubMed

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA, American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2): 70-98. PubMed

General References

Bartley AN, Hamilton SR. Select biomarkers for tumors of the gastrointestinal tract: present and future. Arch Pathol Lab Med. 2015; 139(4): 457-68. PubMed

De Hu Z, Liu X, Liu X, Ding C, Hu C. Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis. Clin Chim Acta. 2014; 433: 44-8. PubMed

Dunbar E, Yachnis AT. Glioma diagnosis: immunohistochemistry and beyond. Adv Anat Pathol. 2010; 17(3): 187-201. PubMed

Dunn BK, Jegalian K, Greenwald P. Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities. Recent Results Cancer Res. 2011; 188: 21-47. PubMed

Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014; 60(12): 1486-99. PubMed

Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer Int J Mol Sci. 2015; 16(6): 14122-42. PubMed

Huse JT, Aldape KD. The evolving role of molecular markers in the diagnosis and management of diffuse glioma. Clin Cancer Res. 2014; 20(22): 5601-11. PubMed

Igbokwe A, Lopez-Terrada DH. Molecular testing of solid tumors. Arch Pathol Lab Med. 2011; 135(1): 67-82. PubMed

Liu H. Application of immunohistochemistry in breast pathology: a review and update. Arch Pathol Lab Med. 2014; 138(12): 1629-42. PubMed

Na Y, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response. Int J Gynecol Cancer. 2009; 19 Suppl 2: S21-9. PubMed

Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009; 19(12): 1351-61. PubMed

Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014; 28(5): 843-53. PubMed

Ringel MD. Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2009; 16(5): 361-6. PubMed

Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010; 51(2): 199-212. PubMed

References from the ARUP Institute for Clinical and Experimental Pathology®

Bahler DW, Szankasi P, Kulkarni S, Tubbs RR, Cook JR, Swerdlow SH. Use of similar immunoglobulin VH gene segments by MALT lymphomas of the ocular adnexa. Mod Pathol. 2009; 22(6): 833-8. PubMed

Chernock RD, Perry A, Pfeifer JD, Holden JA, Lewis JS. Receptor tyrosine kinases in sinonasal undifferentiated carcinomas--evaluation for EGFR, c-KIT, and HER2/neu expression. Head Neck. 2009; 31(7): 919-27. PubMed

Jolanta Jedrzkiewicz, Call TR, Tripp SR, Witt BL. Evaluation of Mu Opioid Receptor Expression via Immunohistochemistry in Various Tumor Types. Knowledge Enterprises Incorporated. Walnut, CA [Accessed: June 2016]

Kikuchi K, Taniguchi E, Chen HH, Svalina MN, Abraham J, Huang ET, Nishijo K, Davis S, Louden C, Zarzabal LA, Recht O, Bajwa A, Berlow N, Suelves M, Perkins SL, Meltzer PS, Mansoor A, Michalek JE, Chen Y, Rubin BP, Keller C. Rb1 loss modifies but does not initiate alveolar rhabdomyosarcoma. Skelet Muscle. 2013; 3(1): 27. PubMed

Kushnir MM, Rockwood AL, Roberts WL, Abraham D, Hoofnagle AN, Meikle W. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem. 2013; 59(6): 982-90. PubMed

Li QK, Nugent SL, Straseski J, Cooper D, Riedel S, Askin FB, Sokoll LJ. Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid carcinoma. Cancer Cytopathol. 2013; 121(8): 440-8. PubMed

Lim MS, Carlson ML, Crockett DK, Fillmore C, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiros J, Szankasi P, Elenitoba-Johnson KS. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood. 2009; 114(8): 1585-95. PubMed

Margraf RL, Calderon FR, Mao R, Wittwer CT. RET mutation scanning update: exon 15. Clin Chem. 2009; 55(11): 2059-61. PubMed

Panarelli NC, Vaughn CP, Samowitz WS, Yantiss RK. Sporadic microsatellite instability-high colon cancers rarely display immunohistochemical evidence of Wnt signaling activation Am J Surg Pathol. 2015; 39(3): 313-7. PubMed

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8): 1160-7. PubMed

Paxton CN, Rowe LR, South ST. Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma Mol Cytogenet. 2015; 8: 60. PubMed

Poirel HA, Cairo MS, Heerema NA, Swansbury J, Aupérin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphaël M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C, FAB/LMB 96 International Study Committee. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009; 23(2): 323-31. PubMed

Slattery ML, Wolff RK, Herrick J, Caan BJ, Samowitz W. Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer. 2009; 125(7): 1698-704. PubMed

Szankasi P, Reading S, Vaughn CP, Prchal JT, Bahler DW, Kelley TW. A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves. J Mol Diagn. 2013; 15(2): 248-54. PubMed

Tomsic J, Senter L, Liyanarachchi S, Clendenning M, Vaughn CP, Jenkins MA, Hopper JL, Young J, Samowitz W, de la Chapelle A. Recurrent and founder mutations in the PMS2 gene. Clin Genet. 2013; 83(3): 238-43. PubMed

Vaughn CP, Baker CL, Samowitz WS, Swensen JJ. The frequency of previously undetectable deletions involving 3' Exons of the PMS2 gene. Genes Chromosomes Cancer. 2013; 52(1): 107-12. PubMed

Walter AW, Ennis S, Best H, Vaughn CP, Swensen JJ, Openshaw A, Gripp KW. Constitutional mismatch repair deficiency presenting in childhood as three simultaneous malignancies. Pediatr Blood Cancer. 2013; 60(11): E135-6. PubMed

Medical Reviewers

Bahler, David W., MD, PhD, Staff Pathologist, Hematopathology at ARUP Laboratories; Associate Professor of Clinical Pathology, University of Utah

Frank, Elizabeth L., PhD, Medical Director, Analytic Biochemistry, Calculi and Manual Chemistry, and Co-Medical Director, Mass Spectrometry at ARUP Laboratories ; Associate Professor of Clinical Pathology, University of Utah

Genzen, Jonathan R., MD, PhD, Co-Medical Director, Automated Core Laboratory at ARUP Laboratories; Assistant Professor of Clinical Pathology, University of Utah

Grenache, David G., PhD, Medical Director, Special Chemistry; Co-Director, Electrophoresis and Manual Endocrinology; Chief Medical Director, Clinical Chemistry at ARUP Laboratories; Associate Professor of Clinical Pathology, University of Utah

Jarboe, Elke, MD, Staff Pathologist, Surgical Pathology and Cytopathology at ARUP Laboratories; Assistant Professor of Anatomic Pathology, Adjunct Assistant Professor, Obstetrics/Gynecology, University of Utah

Kelley, Todd, MD, MS, Medical Director, Molecular Hematopathology and Hematopathology at ARUP Laboratories; Assistant Professor of Clinical Pathology, University of Utah

Lamb, Allen N., PhD, FACMG, Medical Director, Cytogenetics and Genomic Microarray, ARUP Laboratories; Associate Professor of Clinical Pathology, University of Utah

Mao, Rong, MD, Medical Director, Molecular Genetics and Genomics at ARUP Laboratories; Associate Professor of Clinical Pathology and Co-director, Clinical Medical Genetics Fellowship Program, University of Utah

Perkins, Sherrie L., MD, PhD, Senior Vice President, Research and Development; Executive Director, ARUP Institute for Clinical and Experimental Pathology; Chief, Clinical Pathology Division; Section Chief, Hematopathology at ARUP Laboratories ; Vice Chair of Pathology and Professor of Clinical Pathology, University of Utah

Prchal, Josef T., MD, Medical Director, Special Genetics at ARUP Laboratories; Professor, Division of Hematology and Hematologic Malignancies, Dept. of Internal Medicine; Adjunct Professor in Human Genetics and Pathology; Huntsman Cancer Institute Investigator, University of Utah

Salama, Mohamed E., MD, Medical Director, Hematopathology and Immunohistochemistry Staining at ARUP Laboratories; Associate Professor of Clinical Pathology, Director of Hematopathology Fellowship Program, University of Utah

Samowitz, Wade S., MD, Medical Director, Solid Tumor Molecular Diagnostics and Histology, and Staff Pathologist, Anatomic Pathology at ARUP Laboratories; Professor of Anatomic Pathology, University of Utah








































Last Update: December 2016